Analystreport

Castle Biosciences, Inc. (NASDAQ: CSTL) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $94.00 to $80.00. They now have a "buy" rating

Castle Biosciences, Inc. - Common stock  (CSTL) 
Last castle biosciences, inc. - common stock earnings: 3/10 04:05 pm Check Earnings Report